Brought to you by 
Follow-on nets $157.6mm for Ardea Biosciences
13 Feb 2012
Executive Summary
Ardea Biosciences Inc. (working on small-molecule therapeutics for gout, HIV, and cancer) has netted $157.6mm through the follow-on offering of 9.8mm common shares (including the overallotment) at $17 each. Part of the proceeds will support ongoing Phase III trials of the company's lead candidate lesinurad for gout.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Follow-on nets $157.6mm for Ardea Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice